GlassScriptPhysician profile
Justin D Bailey
NPI 1992784243
$4,834.99
in general payments reported to CMS, 2019-2025
39 companies · $746 in 2025
The $746 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $451 · 2021: $641 · 2022: $670 · 2023: $960 · 2024: $956 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,633.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $344.43 | 2020-2025 | Qulipta, Ubrelvy, Synthroid |
| Lilly USA, LLC | $314.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $314.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $221.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $210.68 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.87 | 2019-2025 | Tradjenta, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.73 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $124.66 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $113.19 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $94.88 | 2020-2023 | |
| Dexcom, INC. | $70.61 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $66.90 | 2022 | |
| Abbott Laboratories | $61.89 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.